WO2024179429 - COMBINATION OF DIHYDROBERBERINE AND ERGOTHIONEINE TO REDUCE OR INHIBIT ADVANCED GLYCATION END-PRODUCTS
National phase entry is expected:
Publication Number
WO/2024/179429
Publication Date
06.09.2024
International Application No.
PCT/CN2024/078677
International Filing Date
27.02.2024
Title **
[English]
COMBINATION OF DIHYDROBERBERINE AND ERGOTHIONEINE TO REDUCE OR INHIBIT ADVANCED GLYCATION END-PRODUCTS
[French]
ASSOCIATION DE DIHYDROBERBÉRINE ET D'ERGOTHIONÉINE POUR RÉDUIRE OU INHIBER DES PRODUITS DE GLYCATION AVANCÉE
Applicants **
NANJING NUTRABUILDING BIO-TECH CO., LTD.
Room 1805, Building 1, No. 270 Jiqingmen Street, Gulou District
Nanjing, Jiangsu 210017, CN
Inventors
YI, Ronghua
Room 1805, Building 1, No. 270 Jiqingmen Street, Gulou District
Nanjing, Jiangsu 210017, CN
LIAO, Kylin
Room 1805, Building 1, No. 270 Jiqingmen Street, Gulou District
Nanjing, Jiangsu 210017, CN
WELLS, Shawn
Room 1805, Building 1, No. 270 Jiqingmen Street, Gulou District
Nanjing, Jiangsu 210017, CN
Priority Data
PCT/CN2023/079077
01.03.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1541 | |
| EPO | Filing, Examination | 12041 | |
| Japan | Filing | 535 | |
| South Korea | Filing | 576 | |
| USA | Filing, Examination | 5035 |
Total: 19728 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
It provides methods for reducing or inhibiting advanced glycation end products (AGEs) in a subject, comprising administration to the subject a composition comprising an effective amount of Dihydroberberine or its pharmaceutically acceptable salt, acid, ester, analog or derivative thereof; and an effective amount of Ergothioneine or its pharmaceutically acceptable salt, acid, ester, analog or derivative thereof. It also provides a composition comprising an effective amount of Dihydroberberine or its pharmaceutically acceptable salt, acid, ester, analog or derivative thereof; and an effective amount of Ergothioneine or its pharmaceutically acceptable salt, acid, ester, analog or derivative thereof, for reducing or inhibiting advanced glycation end products (AGEs) in a subject.[French]
L'invention concerne des méthodes de réduction ou d'inhibition de produits de glycation avancée (AGE) chez un sujet, consistant en l'administration au sujet d'une composition contenant une quantité efficace de dihydroberbérine ou de ses sel, acide, ester, analogue ou dérivé pharmaceutiquement acceptables ; et une quantité efficace d'ergothionéine ou de ses sel, acide, ester, analogue ou dérivé pharmaceutiquement acceptables. L'invention concerne en outre une composition contenant une quantité efficace de dihydroberbérine ou de ses sel, acide, ester, analogue ou dérivé pharmaceutiquement acceptables ; et une quantité efficace d'ergothionéine ou de ses sel, acide, ester, analogue ou dérivé pharmaceutiquement acceptables, afin de réduire ou d'inhiber des produits de glycation avancée (AGE) chez un sujet.